BioScrip (BIOS) Stock Rating Upgraded by ValuEngine
BioScrip (NASDAQ:BIOS) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Thursday.
A number of other research firms also recently issued reports on BIOS. SunTrust Banks reaffirmed a “buy” rating and set a $3.00 price objective on shares of BioScrip in a report on Friday, November 3rd. BidaskClub downgraded shares of BioScrip from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. Zacks Investment Research downgraded shares of BioScrip from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Finally, Jefferies Group reissued a “buy” rating and issued a $4.00 price target (up from $3.00) on shares of BioScrip in a report on Thursday, August 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $3.60.
BioScrip (BIOS) traded up $0.11 during midday trading on Thursday, reaching $2.62. 1,618,862 shares of the company traded hands, compared to its average volume of 1,740,347. BioScrip has a twelve month low of $0.98 and a twelve month high of $3.39. The company has a debt-to-equity ratio of -6.11, a current ratio of 1.91 and a quick ratio of 1.60.
In related news, Director Coliseum Capital Management, L sold 2,846,941 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $2.93, for a total value of $8,341,537.13. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Michael G. Bronfein sold 27,000 shares of the business’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $2.69, for a total value of $72,630.00. Following the completion of the sale, the director now owns 129,669 shares in the company, valued at $348,809.61. The disclosure for this sale can be found here. 0.80% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently made changes to their positions in BIOS. Gilder Gagnon Howe & Co. LLC increased its position in shares of BioScrip by 248.4% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 15,211,136 shares of the company’s stock valued at $41,298,000 after buying an additional 10,845,410 shares during the period. Alta Fundamental Advisers LLC increased its position in shares of BioScrip by 36.9% in the second quarter. Alta Fundamental Advisers LLC now owns 3,035,164 shares of the company’s stock worth $8,240,000 after purchasing an additional 818,000 shares during the last quarter. Fuller & Thaler Asset Management Inc. bought a new position in shares of BioScrip in the third quarter worth approximately $1,642,000. FMR LLC increased its position in shares of BioScrip by 10.8% in the second quarter. FMR LLC now owns 5,323,231 shares of the company’s stock worth $14,453,000 after purchasing an additional 520,231 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of BioScrip in the third quarter worth approximately $857,000. Hedge funds and other institutional investors own 84.44% of the company’s stock.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.